Deuruxolitinib in Alopecia Areata: Trial Data, Onset of Action, and Adverse Event Management

In 'Deuruxolitinib in Alopecia Areata: Trial Data, Onset of Action, and Adverse Event Management,' the expert dermatologist examined the following critical questions:

Deuruxolitinib was most recently approved in 2024. What were the key results from the clinical trials?

How do you weigh in deuruxolitinib's faster onset of action compared with other JAK inhibitors in your clinical practice?

What are the main adverse events of Janus kinase (JAK) inhibitors that you are monitoring for in clinical practice and how are you managing them?

Dr. Mostaghimi discussed the clinical trial data for deuruxolitinib, a JAK1/2 inhibitor dosed at 8 mg twice daily, which demonstrated a faster onset of action compared with baricitinib and ritlecitinib — achieving mid-30% Scalp Area and Hair Loss Tool (SALT) score less than 20 response rates at 24 weeks, approximately 3 months earlier than baricitinib at 36 weeks. Dr. Mostaghimi noted that deuruxolitinib is particularly well-suited for patients with time-sensitive goals, such as an upcoming event, or those seeking maximal and rapid hair regrowth, though its twice-daily dosing and prerequisite genetic testing require additional patient commitment. He then provided a detailed overview of adverse event monitoring for all three approved JAK inhibitors, including baseline and follow-up assessments for complete blood count (CBC), lipid panels, hepatitis, and tuberculosis, and outlined practical strategies for managing dyslipidemia, thrombocytosis, and thrombosis risk through shared decision-making and modifiable risk factor reduction.

Throughout the conversation, the expert provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, 'From Patient Selection to Future Therapies: JAK Inhibitors in Alopecia Areata,' further explores alopecia areata, highlighting how clinicians can individualize JAK inhibitor selection based on patient-specific factors, when and how to switch between agents, and what emerging data and novel therapeutic approaches may shape the treatment landscape over the next 5 years.